| | Finding the right patients for a particular clinical trial involves precision, timeliness and is one of the most important hurdles to successful clinical development. Learn more about early indicators of efficacy and more from a free white paper by TD2. |
JPM: Sanofi inks $1.1B Kymab buyout to bag midphase eczema drug Lilly hails Alzheimer's win with donanemab, boasting 'significant slowing of decline' JPM: Biogen bullish on Alzheimer’s drug approval, sees Lilly data as a positive, despite AdComm rejection JPM: Bluebird to spin off cancer therapies into new company JPM: Regeneron has spoken with the FDA about odronextamab hold, hopes to get patients back soon Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling Vaccines aren't enough. We need more COVID-19 treatments, too: Fierce JPM Week Fierce JPM Week: Koller on what 2021 holds for insitro, machine learning and working virtually Fierce JPM Week: Even amid COVID-19 fight, oncology will be 'ripe' in 2021, Bristol CMO says JPM: Sanofi grabs a British biotech, Regeneron hopes for FDA hold lift, Bluebird puts its eggs in two baskets, and more JPM: Microsoft signs on to Verily, Broad Institute’s Terra open research platform Synairgen's inhaled interferon for COVID-19 enhances short, harmless version of virus entry point: study Featured Story | By Nick Paul Taylor Sanofi has struck a deal to buy Kymab for $1.1 billion upfront. The takeover will give Sanofi full global rights to an anti-OX40L monoclonal antibody that improved outcomes in atopic dermatitis patients in a midphase clinical trial last year. read more |
| |
|---|
|
| Thank you to Catalent for sponsoring this year's JPM 2021 coverage. |
Top Stories By Ben Adams The amyloid theory continues to grasp at life as Eli Lilly has unveiled new phase 2 data from donanemab that show it can help Alzheimer’s disease patients by clearing these plaques out of the brain. read more By Ben Adams Biogen’s C-suite remains bullish that its controversial Alzheimer’s disease drug aducanumab will be approved in the coming weeks, citing a rare glimmer of hope from a similar drug from Eli Lilly that posted broadly positive data today. read more By Nick Paul Taylor Bluebird bio is planning to spin off its oncology assets into a new publicly traded company. The move follows a series of operational missteps that have delayed patient access to once-hyped therapies. read more By Ben Adams Regeneron’s chief scientific officer has told investors that the ball is in the FDA’s court after looking to “fulfill their need” to lift the enforced pause on its cancer study. read more By Nick Paul Taylor Atalanta Therapeutics has broken cover with $110 million from a series A round and partnerships with Biogen and Genentech. The biotech secured the deals and funding on the strength of evidence it can durably silence genes in the brain. read more By Amirah Al Idrus The two vaccines and multiple therapeutics cleared for emergency use aren't nearly enough to stop COVID-19. We need an arsenal of drugs that work in different ways to attack a complex, multifaceted illness, speakers on a Fierce JPM Week panel said. read more By Conor Hale While 2020 has changed the way we live, the pandemic may also deliver lasting changes to how we work—and, as machine learning aims to have a larger impact on the life sciences, they may be changes for the better, according to insitro founder and CEO Daphne Koller. read more By Amirah Al Idrus For the biopharma industry, 2020 was many things, but for Samit Hirawat, chief medical officer of Bristol Myers Squibb, three things stand out: collaboration, adaptation and evolution. read more By Ben Adams,Amirah Al Idrus,Conor Hale We’re used to formal clothing expensive hotels and meeting venues that solitary confinement cells look spacious, with the offer of $20 coffees (if spending a minimum of $100), but this year, things are very different. read more By Conor Hale Verily and the Broad Institute of MIT and Harvard hope to dramatically boost the reach of their open-source biomedical research platform, through a new partnership with Microsoft. read more By Arlene Weintraub Interferon increases levels of the cell surface protein ACE2, which serves as the entry point for COVID-19, raising concerns that Synairgen and others developing inhaled interferon-based treatments might ultimately fail. Now, a U.K. team has discovered interferon only raises levels of a short form of ACE2 that may actually be protective. read more Resources Sponsored By: Polpharma Biologics Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards. Sponsored By: Blue Matter Biopharma companies in rare diseases: How to maximize the odds of success by becoming a valued member of the unique “rare disease ecosystem.” Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: GenScript A significant number of new treatments have been approved so far, but some manufacturing and regulatory guidelines pose challenges for advanced therapies, leading to poor production yields. Sponsored by: Catalent Cell and gene therapies hold the promise to offer novel therapeutic avenues for individuals facing serious medical conditions, but bringing them through the clinical trial process introduces a level of supply chain risk and complexity. Sponsored by: AllianceRx Walgreens Prime Gene and cell therapy are shifting paradigms for manufacturers, patients, healthcare providers and pharmacies. We invite you to learn more by reading Gene and Cell Therapy: A New Age of Medicine. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Metabolon Learn six ways metabolomics provides greater confidence, higher success rates and complements the work of your in-house teams for your drug development pipeline. Sponsored by: Covance Download the whitepaper to learn how your safety organization can implement automation technologies to enable process and cost efficiencies, improve resource allocation and ensure compliance and quality. Sponsored By: BBK Worldwide The BBK Worldwide Study Voices 2020 survey gives voice to the healthcare consumer in the wake of COVID-19 and reveals important insights for clinical trial enrollment and engagement. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Rousselot This infographic describes the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments. Sponsored by: Aldevron Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience. Sponsored By: Outer Edge Technology A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Fierce JPM Week January 11–13, 2021, 10AM ET | Virtual Event Virtual Clinical Trials Summit February 9-10, 2021 | Virtual Event | 